Which listed companies delivered standout performance in their 2023 annual results?

• Revenue in the Asia-Pacific, Middle East and Africa (APMEA) region grew by 1.8%, driven by growth in Pakistan, Indonesia, New Zealand, Nigeria, and Gulf Cooperation Council countries. • Although facing challenges, the U.S. market showed signs of market share recovery through commercial investments. 1. Product Innovation and Regulatory Approvals: • The Vuse Alto device and tobacco-flavored consumer products received marketing authorization from the U.S. FDA, affirming their suitability for public health protection. • The Group continues to invest in product innovation and expects to launch new products in the second half of the year. 1. Financial Flexibility and Shareholder Returns: • A sustainable share buyback program was launched through partial monetization of ITC shares, with planned investments of £700 million in 2024 and £900 million in 2025. • The Group maintains strong cash flow and expects to continue returning cash to shareholders. Challenges 1. Illicit Disposable Vaping Products: • The U.S. market is affected by sales of illicit disposable vaping products, placing pressure on the legal market. 1. Exchange Rate Volatility: • Reported revenue and profit were negatively impacted by exchange rate fluctuations—particularly following the divestiture of operations in Russia and Belarus, as well as movements in the U.S. dollar, euro, and British pound. 1. Market Exits: • In 2023, the Group sold its businesses in Russia and Belarus, affecting revenue in the first half of 2024. 1. Litigation and Regulatory Risks: • The Group faces multiple lawsuits and regulatory challenges, including regulatory interactions with the FDA, a Canadian class-action lawsuit, and the UK’s Franked Investment Income Group Litigation. 1. Macroeconomic Pressures: • Cigarette volume declined in the U.S. market, partly due to macroeconomic pressures and reduced consumer spending. Analysis Despite these challenges, BAT achieved improved returns by focusing on “quality growth” and making more targeted investments across all three of its new product categories.

Neuroscience company Alto Neuroscience files for NYSE IPO: no revenue yet, $25.09 million net loss in first nine months of 2023

Built upon over a decade of methodology and data accumulation, Alto Neuroscience’s AI platform identifies patients likely to respond to treatment and leverages biomarkers to drive drug development. Alto Neuroscience identifies biomarkers—and constructs its pipeline—in a closely integrated manner, focusing intently on core domains of psychological function (cognition, emotion, and sleep) and their underlying brain circuits. Patients are stratified using functional brain metrics such as electroencephalography (EEG), alongside behavioral and computerized tests administered via wearable devices, enabling precise matching with appropriate Alto therapeutics. According to its prospectus, Alto Neuroscience generated $210,000 in revenue in 2021, but reported zero revenue from 2022 through the present. Alto Neuroscience recorded operating losses of $12.06 million and $29.19 million in 2021 and 2022, respectively; net losses totaled $9.19 million and $27.71 million for those years. In the first nine months of 2023, Alto Neuroscience incurred a net loss of $25.09 million, compared to a net loss of $20.06 million in the same period of 2022. Cumulative Fundraising Exceeds $100 Million Since its founding, Alto Neuroscience has raised over $100 million in funding. In January 2023, Alto Neuroscience announced the completion of a $25 million equity investment, bringing its Series B round total to $60 million. Alto also entered into a $35 million credit facility with K2 HealthVentures, providing access to additional capital and flexibility as the company advances its clinical-stage pipeline. In late November 2023, Alto Neuroscience announced a $45 million Series C financing round, led by InVivium Capital, with other new investors including Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments.

Alto Ingredients (NASDAQ:ALTO) Releases Earnings Results, Beats Expectations By $0.07 EPS

12 hours ago

Alto Ingredients beat Q3 earnings expectations with $0.16 EPS and $257.89M revenue, securing five consecutive quarters of positive income. While gross profit fell due to weak crush margins, the company expects $20M in 2026 tax credit earnings.

MarketBeat

2026-08-08

Alto Ingredients Beats EPS by 76%, Analysts Raise Price Target

2026-08-09

Alto Ingredients Beats Earnings Forecasts, Analysts Update Models

2026-11-05

Alto Ingredients (NASDAQ:ALTO) Releases Earnings Results, Beats Expectations By $0.07 EPS

Alto Ingredients (NASDAQ:ALTO) Releases Earnings Results, Beats Expectations By $0.07 EPS

FAQ